Towards Healthcare
Myasthenia Gravis Treatment Market to Drive USD 3.29 Bn by 2034

Myasthenia Gravis Treatment Market Rising Diagnostics and Targeted Therapies

According to forecasts, the global myasthenia gravis treatment market will grow from USD 1.55 billion in 2024 to USD 3.29 billion by 2034, with an expected CAGR of 7.84%. The myasthenia gravis treatment market is growing due to the rising prevalence of myasthenia gravis (MG), the growing aging population, and enhanced diagnostic abilities. North America is dominant in the market due to the presence of significant healthcare research and development services.

Content

  • Insight Code: 6298
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The myasthenia gravis treatment market holds a valuation of USD 1.67 billion as of 2025, and will expand to USD 3.29 billion by 2034, achieving a CAGR of 7.84% between 2024 and 2034.

North America is currently leading the myasthenia gravis treatment market due to a robust healthcare infrastructure and increased healthcare expenditure.

Some key players include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals, Plc., Novartis, Pfizer, Inc., and AbbVie Inc.

In myasthenia gravis, the immune system mistakenly makes antibodies that stop the neurotransmitter acetylcholine from communicating with muscles.

Ministry of Health and Family Welfare, FDA, WHO, PIB, CDC.
Any Questions